Page 233 - HIVMED_v21_i1.indb

Page 6 of 11 Review Article

Strength/weakness of design The article only focused on one aspect of mathematical models and ignored other aspects, which might influence cost implications. The study also used a simulation model combining clinical and cost data for HIV treatment into this model and then used it to project survival and costs in a hypothetical group of South African HIV-positive patients. This strengthened the findings of the study because simulation provides a unique opportunity

Major outcomes of study In settings where immediate implementation of all the new WHO treatment guidelines is not feasible, ART initiation at CD4 < 350 cells/µL provides the greatest short- and long-term survival advantage and is highly cost-effective, however considering the high HIV-incidence and prevalence in South Africa meeting the targets timely would be a challenge. Limited infra-structure in implementing the 2010 guidelines was a challenge. When adopti

Study location South Africa Botswana Cameroon Central African Republic Kenya Lesotho Malawi Mozambique South Africa Swaziland Uganda United Republic of Tanzania Zambia Zimbabwe Lesotho

The article considers what to do first in resource- limited settings where immediate implementation of all the 2010 WHO recommendations is not feasible considering that many countries in SSA were still struggling to implement The ART need estimates based on ART-eligibility criteria promoted by the 2010 WHO guidelines were compared with the need estimates based on the 2006 WHO guidelines. comparing nurse-based ART initiation at health centres in ter

Study focus 2006 guidelines. The study aimed at number of drug side effects.

Type of study Cost- effectiveness and survival analysis model Retrospective study. Time series estimates of ART-initiation models Retrospective cohort analysis

Study objectives The study aimed to answer the question whether countries should begin by replacing stavudine with tenofovir or by making CD4 count monitoring universally available as recommended by the 2010 WHO guidelines. Use of a model-based analysis with data from South Africa to project the clinical and economic outcomes of alternative stepwise implementation scenarios towards the 2010 WHO and ART guidelines The study estimated the number

TABLE 1 (Continues...): Summary of studies. Theme identified Guidelines year Timely implementation of 2010 WHO and ART initiation policy guidelines at country level Adoption of WHO and ART initiation policy guidelines at national level Barriers and facilitators to WHO-policy implementation Timely implementation of 2006 and WHO and ART initiation 2010 policy guidelines at country level Adoption of WHO and ART initiation policy guidelines at country lev

Walensky
Stanecki
and year
Paper 11
Paper 12
Author
et al. 20
et al. 5
2010
2010
http://www.sajhivmed.org.za 225 Open Access Labhardt et al. 21 2012 Paper 13